Measuring symptomatic relief in men with lower urinary tract symptoms
Most currently used drugs have been given too easy a ride

Marco H Blanker general practitioner and epidemiologist¹, Kenny R van Deventer editor², Dick Bijl chief editor²

¹Department of General Practice, University of Groningen, University Medical Centre Groningen, PO Box 196, NL 9700 AD, Groningen, Netherlands; ²Geneesmiddelenbulletin, Mercatorlaan Utrecht, Netherlands

Lower urinary tract symptoms are common in the ageing population and have many causes.¹ In men the various symptoms are still often attributed to benign prostatic hyperplasia, whatever their true cause² and despite the remarks repeatedly made about nomenclature.¹ Recently published guidelines and reviews on the evaluation and treatment of men with lower urinary tract symptoms rate four categories of drugs as efficacious: α blockers, 5-α reductase inhibitors, anticholinergics, and phosphodiesterase-5 inhibitors.¹²³

We are surprised at how highly these drugs are recommended given how well they work. While treatment effects are reported as being significantly better than those of placebo, we wonder whether the small differences in patient-reported symptom scores are perceptible to patients. Most drugs used for these symptoms were investigated using the International Prostate Symptom Score (IPSS), equivalent to the American Urologic Association (AUA) Symptom Index. This index has seven questions and yields scores ranging from 0 to 35, with higher scores indicating more severe symptoms. About 20 years ago, Barry and colleagues estimated the smallest perceptible change in the AUA symptom index in 1222 men participating in randomised controlled trials investigating treatment for benign prostatic hyperplasia.⁴ Patients considered a 3 point fall in symptom score a “slight” improvement (table 1), and since then a 3 point change in score has been regarded as clinically relevant when assessing treatments. This cut-off has never been challenged.

What matters to patients

From the patient’s viewpoint, it seems highly arguable that a slight improvement should be regarded as clinically relevant. Who would willingly take any drug that carries the risk of (more or less) severe side effects and drug interactions,⁵ for only a slight improvement in symptoms? In nearly all randomised trials of drugs for lower urinary tract symptoms, changes in different treatment arms are presented as mean scores. In most cases, the differences between active and placebo treatments are reported as “statistically significant,” but we doubt this usually reflects a clinically relevant change. We found that a difference of more than 3 points was reported in only four out of 28 studies.⁶⁻⁷ In these studies the mean decrease in the IPSS score was 6.8 (tamsulosin v placebo),³ 3.1 (dopazosin and finasteride v placebo, but in combination not better than doxazosin monotherapy),⁹ 3.9 (terazosin v placebo),¹⁰ and 3.1 (terazosin and finasteride v placebo, but in combination not better than terazosin monotherapy).¹¹ Therefore, hardly any of the available drugs is better than placebo at a “clinically relevant” level. At best, there is less than a “slight” difference in favour of active treatment.

Because published studies report mean scores, some participants will have had larger improvements. However, from all available data it remains unclear how many participants taking active medication would have experienced moderate or substantial improvement in symptoms. Such information is essential to provide patients with reliable information about treatment. Another study examined the effects on symptom worsening and complication rates over four years. Even in the high risk patients included in this trial, the complication rate was low. As a consequence, the numbers needed to treat derived from this trial were very high.¹²

There is an urgent need to publish data on the efficacy of drugs prescribed for lower urinary tract symptoms, in particular on the chances of achieving a clinically relevant change. We believe that a “moderate” (5 points) or “marked” (9 points) improvement (as defined by Barry and colleagues) should be used to define clinically relevant change, and meta-analyses of large randomised trials using this cut-off should be performed. We encourage authors and drug companies to make their data available for such analysis. In addition, future studies testing new treatments could use this cut-off in power analyses. This would enable physicians to provide better treatment and advice for the increasing number of men who consult them for lower urinary tract symptoms.
Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: none.

Provenance and peer review: Not commissioned; externally peer reviewed.

1 National Institute for Health and Care Excellence. The management of lower urinary tract symptoms in men: NICE guideline No CG97. NICE, 2010.

2 Hollingsworth JM, Wilf TI. Lower urinary tract symptoms in men. BMU 2014:349:g4474.

3 Abrams P, Cardozo L, Fall M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostate obstruction. Eur Urol 2013:64:118-40.

4 Rees J, Bultrini M, Challacombe B. The management of lower urinary tract symptoms in men. BMU 2014:349:g3861.

5 Oelke M, Bachmann A, Descasaeld A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostate obstruction. Eur Urol 2013:64:118-40.

6 Barry MJ, Willfirdo WD, Chang Y, Machi M, Jones KM, Walker-Corkery E, et al. Benign prostate hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostate hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4.

7 Bird ST, Delaney JA, Brophy JM, Eltimman M, Skelton SG, Hartmes AG. Tamsulosin treatment for benign prostate hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMU 2013:347:h3320.

8 Mohanty NK, Nayak RL, Mahotra V, Arora RP. A double-blind placebo controlled study of tamsulosin in the management of benign prostate hyperplasia in an Indian population. Ann Col Surg Hong Kong 2003;7:98-93.

9 Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostate hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26.

10 Roehrborn CG, Cesterling JE, Aubach S, Kaplan SA, Lloyd UK, Milam DE, et al. The Hytrin Community Assessment Trial: a one-year study of terazosin versus placebo in men with symptomatic benign prostate hyperplasia. Urology 1996;47:159-68.

11 Lopez H, Wilford WD, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostate hyperplasia. N Engl J Med 1996;335:533-9.

12 McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of terazosin, finasteride, and combination therapy on the clinical progression of benign prostate hyperplasia. N Engl J Med 2003;349:2897-98.

13 Chapple CR, Ali Shukri SH, Gattagno B, Holmes S, Martinez-Sagasta JM, Scapra RM et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia (LUTS/BPH): Efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol Supp 2005;4:S3 44.

14 Dijaan B, Milani S, Davies J, Boldsouk J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Supp 2005;4:S1 68.

15 Lopez H. Phases III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900.

16 Narayan P, Tewar A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998;159:170-9.

17 Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001;58:953-9.

18 Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006;97:754-41.

19 Van Kemenade P, Jardin A, Lavel-KJU, Van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg three daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALCORT Study Group. Eur Urol 2000;37:306-13.

20 Abrams P, Schater W, Trommel TA, Barrett DM, Heddin H, Rolfena H, et al. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group. J Urol 1995;161:1513-7.

21 Bynnes CA, Morrison AS, Liss CL, Lippert MC, Gillerwater JY. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. Community based study of Proscar. Clin Ther 1995;17:956-69.

22 McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holltowarie HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63.

23 Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Pemartul AJ, Aitman SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). CMAJ 1996;155:1251-9.

24 Polat O, Ozszy I, Gul O, Demiel AB, Aybakrty A. Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase. Int Urol Nephrol 1997;29:525-30.

25 McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2897-98.

26 Roehrborn CG, McConnell JD, Saltzman B, Bengner D, Gray T, Narayan P, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002;42:1-6.

27 Gormley GJ, Stener E, Bruskewitz RC, Impero-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Eng J Med 1992;327:1185-91.

28 Roehrborn CG, Boyle P, Nickle JC, Hoeker N, Andriole G, ARISA001 ARISA002 and ARISA003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.

29 Nickle JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the enlarged prostate international comparator study (EPICIS). BJU Int 2011;108:388-94.

30 Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z, Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;291:2319-28.

31 Porsi H, Kim ED, Casab R, Mironne V, Socrast RJ, Xu L, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms and overactive bladder: a randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-13.

32 Egeride RB, Aubach S, Roehrborn CG, Costa P, Garza MS, Eiser AL, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-9.

33 Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Witkop L. Monotherapy with tadalafil or combination therapy with tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25.

Cite this as: BMJ 2014;349:g6664

© BMJ Publishing Group Ltd 2014
Table

Table 1 | Relation between mean absolute change in American Urologic Association symptom index (range 0 to 35) and patients’ 13 week global assessment of change

| Mean (SE) change in symptom score* | Patient assessment of improvement |
|-----------------------------------|----------------------------------|
| - 8.8 (0.34)                      | Marked                           |
| - 5.1 (0.29)                      | Moderate                         |
| - 3.0 (0.27)                      | Slight                           |
| + 2.7 (0.93)                      | Worse                            |

* Change between baseline and follow-up assessment in 1222 men participating in randomised controlled trials (derived from Barry et al).